Literature DB >> 33510591

Triage of urology service to cope with COVID-19 pandemic: A single institution study.

Muhammad Waqar1, Kelly Ong1, Amr Moubasher1, Omer Farooq Rehman2, Kamran Faisal Bhopal3, Jonathan Makanjuola1.   

Abstract

Almost a year ago, no one has ever heard of COVID-19 but now, every individual in the world is familiar with this term. It is far from over and yet, it has affected every aspect of human life. The Department of Urology at King's College Hospital London provides all types of urology care ranging from benign to cancer treatments to the community. However, this service was badly affected by COVID-19. Policies were made by the experts in the field to reduce patient traffic in the hospital and at the same time, attempting to ensure appropriate and timely treatment was provided to patients suffering from urological conditions requiring urgent attention. In this article, we discuss the triage guidelines set up at our centre. Treatments for benign conditions such as kidney stones were delayed for 3-6 months. For the first time, telephone and video clinics were setup to follow-up patients with benign conditions. Urological emergencies such as acute urinary retention and priapism were discharged from accidental and emergency department after treatment. Small T1 renal cancers were put on surveillance, whereas T2 and T3 renal cancers were offered nephrectomy at a COVID-free specialized center. Transurethral removal of bladder tumor was offered only for solid or actively bleeding tumor. High risk prostate cancer patients were started on hormonal therapy and radiotherapy was only offered for spinal cord compression secondary to metastasis. Low and intermediate non-metastatic prostate cancers were placed on active surveillance. Patients with testicular tumor continued to have immediate inguinal orchidectomy. The multi-disciplinary meetings were done remotely using blue jeans software®. These steps not only strive to provide adequate and timely urology care to patients but also protect health care workers and prevent the spread of COVID-19.
Copyright © 2021 Waqar et al.

Entities:  

Keywords:  COVID-19; bladder cancer; kidney cancer; testicular cancer

Year:  2021        PMID: 33510591      PMCID: PMC7838939          DOI: 10.17179/excli2020-3135

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


  10 in total

1.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

2.  Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer.

Authors:  Catharina A Goossens-Laan; Anna M Leliveld; Rob H A Verhoeven; Paul J M Kil; Geertruida H de Bock; Maarten C C M Hulshof; Igle J de Jong; Jan Willem W Coebergh
Journal:  Int J Cancer       Date:  2014-01-25       Impact factor: 7.396

3.  Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.

Authors:  Francis Thomas; Aidan P Noon; Naomi Rubin; John R Goepel; James W F Catto
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

4.  The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.

Authors:  Roy Mano; Emily A Vertosick; Abraham Ari Hakimi; Itay A Sternberg; Daniel D Sjoberg; Melanie Bernstein; Guido Dalbagni; Jonathan A Coleman; Paul Russo
Journal:  Urol Oncol       Date:  2016-01-12       Impact factor: 3.498

5.  Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

Authors:  Zachary Klaassen; Ashish M Kamat; Wassim Kassouf; Paolo Gontero; Humberto Villavicencio; Joaquim Bellmunt; Bas W G van Rhijn; Arndt Hartmann; James W F Catto; Girish S Kulkarni
Journal:  Eur Urol       Date:  2018-07-13       Impact factor: 20.096

Review 6.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Authors:  Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup
Journal:  Eur Urol       Date:  2019-08-20       Impact factor: 20.096

7.  Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic.

Authors:  Kristian D Stensland; Todd M Morgan; Alireza Moinzadeh; Cheryl T Lee; Alberto Briganti; James W F Catto; David Canes
Journal:  Eur Urol       Date:  2020-04-09       Impact factor: 20.096

8.  Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Authors:  Ashish M Kamat; Joaquim Bellmunt; Matthew D Galsky; Badrinath R Konety; Donald L Lamm; David Langham; Cheryl T Lee; Matthew I Milowsky; Michael A O'Donnell; Peter H O'Donnell; Daniel P Petrylak; Padmanee Sharma; Eila C Skinner; Guru Sonpavde; John A Taylor; Prasanth Abraham; Jonathan E Rosenberg
Journal:  J Immunother Cancer       Date:  2017-09-28       Impact factor: 13.751

Review 9.  Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres.

Authors:  Riccardo Campi; Daniele Amparore; Umberto Capitanio; Enrico Checcucci; Andrea Salonia; Cristian Fiori; Andrea Minervini; Alberto Briganti; Marco Carini; Francesco Montorsi; Sergio Serni; Francesco Porpiglia
Journal:  Eur Urol       Date:  2020-04-11       Impact factor: 20.096

10.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Authors:  Wenhua Liang; Weijie Guan; Ruchong Chen; Wei Wang; Jianfu Li; Ke Xu; Caichen Li; Qing Ai; Weixiang Lu; Hengrui Liang; Shiyue Li; Jianxing He
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.